Merck/Eisai's Keytruda/Lenvima combo meet endpoints in late-stage uterine cancer study

 

• Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) have announced data demonstrating positive top-line results from Phase 3 KEYNOTE-775/Study 309, evaluating Merck's Keytruda plus Eisai's Lenvima in patients with advanced endometrial cancer following at least one prior platinum-based regimen.
• The study met its primary and secondary endpoints, and demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival and objective response rate versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel).
• Safety profile of drug combination was consistent with previously reported studies.
• Merck and Eisai will discuss these data with regulatory authorities, with the intent to submit marketing authorization applications, and plan to present these results at an upcoming medical meeting.
• Earlier today, BioLineRx's motixafortide and Keytruda combination trial reported median OS of 6.5 months compared to historical data of 4.7 months in pancreatic cancer.
• Last month, both the companies also announced that Keytruda plus Lenvima combination met endpoints in advanced renal cell carcinoma study.
• https://seekingalpha.com/news/3644799-merck-eisais-keytruda-and-lenvima-combo-meet-endpoints-in-late-stage-uterine-cancer-study